# Application of Brachytherapy in Postoperative Treatment of Keloid‐Prone Patients

**Authors:** Hanhan Tian, Tingting Dai, Changhua Yu

PMC · DOI: 10.1111/jocd.70804 · 2026-03-19

## TL;DR

This study shows that a single high-dose brachytherapy session after surgery may effectively treat keloids with minimal side effects.

## Contribution

The study introduces a new outpatient treatment protocol using high-dose brachytherapy for keloid-prone patients.

## Key findings

- A total effective rate of 93.75% was achieved with 25 cured and 5 improved cases.
- No severe radiation-induced skin reactions or hormonal abnormalities were observed.
- The treatment was associated with a high response rate and no severe adverse events.

## Abstract

Keloids are benign fibroproliferative tumors that often recur after surgical excision. Combining surgery with postoperative radiotherapy has emerged as a potential treatment strategy, though optimal radiotherapy protocols remain debated.

This study aims to preliminarily evaluate the efficacy and safety of a single high‐dose brachytherapy session administered within 8 h after surgical excision in keloid‐prone patients in a retrospective setting.

A retrospective case series analysis was conducted on 32 patients who underwent surgical excision of keloids followed by a single 8 Gy Ir‐192 brachytherapy session within 8 h postoperatively. Treatment outcomes and adverse reactions were assessed over a 1‐year follow‐up period.

Among the 32 patients, 25 were cured, 5 showed significant improvement, and 2 were ineffective, yielding a total effective rate of 93.75%. No severe radiation‐induced skin reactions (Grade III/IV) or abnormalities in thyroid or estrogen levels were observed.

In this small retrospective series, single‐dose 8 Gy brachytherapy administered within 8 h after surgical excision was associated with a high response rate and no severe adverse events. These findings suggest it may be a potentially useful outpatient treatment option for keloids, though further comparative studies are needed to confirm its efficacy and safety.

## Linked entities

- **Chemicals:** Ir-192 (PubChem CID 66373)

## Full-text entities

- **Genes:** PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}
- **Diseases:** ulcer (MESH:D014456), sensory loss (MESH:C580162), Keloid-Prone (MESH:D007627), hypertrophic scars (MESH:D017439), dermatitis (MESH:D003872), blisters (MESH:D001768), itching (MESH:D011537), erythema (MESH:D004890), malignancy (MESH:D009369), skin injury (MESH:D000069836), necrosis (MESH:D009336), Scar (MESH:D002921), pigmentation (MESH:D010859), pain (MESH:D010146), hypertrophy (MESH:D006984), skin reactions (MESH:D012871), radiation dermatitis (MESH:D011855), edema (MESH:D004487)
- **Chemicals:** Ir-192 (MESH:C000615087)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13003190/full.md

---
Source: https://tomesphere.com/paper/PMC13003190